News

Denosumab Not Cost Effective in Solid Tumor Bone Metastases


 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Discussing the poster at the ASCO meeting, Dr. Thomas J. Smith of the Massey Cancer Center at Virginia Commonwealth University, Richmond, said it "raises some significant concern about money-driven value in metastatic breast cancer treatment."

Dr. Smith said that the study raises questions about physicians’ ability to negotiate prices, and how to use these data in making decisions. "I can tell you that at most hospitals, most P&T [pharmacy and therapeutics] committees have wrestled exactly with this, ... and where does this fit in pathway-driven managed care, where you get a fixed amount to take care of these patients?" he said.

That the analysis was funded by the maker of zoledronic acid also was a concern. "So I would wait to draw conclusions until this has been through peer review," Dr. Smith said.

The prostate cancer study found that denosumab marginally improved quality of life (+0.0043 QALYs) relative to zoledronic acid, and reduced costs of SREs by $1,924 based on a calculation that these would cost $7,604 with denosumab vs. $9,528 with zoledronic acid over 27 months of treatment. To achieve those benefits, the patient would have to invest more than $7,313 in additional drug costs with denosumab, and thus incur a net cost of $5,390 over 27 months, according to the study.

Novartis, the maker of zoledronic acid, sponsored both studies. Mr. Carter and Dr. Snedecor disclosed consultant or advisory roles with Novartis. One of their coauthors was a Novartis employee with stock ownership. Mr. Botteman disclosed consultant or advisory roles with Pharmerit. Dr. Smith disclosed research funding from the American Cancer Society and the National Cancer Institute.

Pages

Recommended Reading

Study: Flaxseed Bars Not Effective in Reducing Hot Flashes
MDedge Family Medicine
Screen Breast Cancer Patients for Depression
MDedge Family Medicine
Video Report: Recession Impacts Cancer Screening, Treatment
MDedge Family Medicine
New Cancer Patients Struggle to Get Appointments
MDedge Family Medicine
FDA Adds Warnings About High-Grade Prostate Cancer to BPH Drug Labels
MDedge Family Medicine
FDA Approves Test for HER2 Gene in Breast Cancer Tissue
MDedge Family Medicine
European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer
MDedge Family Medicine
Smoking Bans, Taxes Could Save Nearly $2 Billion in Health Costs
MDedge Family Medicine
Iniparib Loses Blockbuster Image in Triple-Negative Breast Cancer
MDedge Family Medicine
FDA Approves Cancer Drugs Faster Than European Agency
MDedge Family Medicine